Are You Looking To invest Pharmeasy Unlisted Shares? By Planify
                     PharmEasy IPO
What Is Pharmeasy
• API Holding is India's leading digital healthcare platform, operating an integrated, 
end-to-end business that provides the solutions for healthcare needs of consumers 
across the critical stages. It's unified data platforms and supply chain capabilities 
etc enables it to service each of its stakeholder in the healthcare value chain.
• The company operates a consumer healthcare app called PharmEasy which 
enables on demand, home delivery of pharmaceutical products to the customers.
• The company has grown a lot since its inception and presently, in 2021, has 26 
subsidiaries including Aknamed, Docon and Thyrocare.
• API Holdings is the holding entity for the PharmEasy group. API Holding was 
incorporated on March 31, 2019 and heads its operations from its office in Mumbai, 
Maharashtra.
Pharmeasy IPO Details
• API Holdings Limited has filed its DRHP on 8th November 2021 and will be coming 
out with their IPO in this financial year.
• According to the DRHP the entire IPO only consists of a fresh issue, which means 
that none of the existing Pharmeasy shareholders of the company are selling 
their stake in the company. Their decision to not to cash out during the IPO 
indicates confidence among company’s investors about the growth potential of the 
company.
• The company may also consider a further issue of equity shares via a private 
placement of up to ₹1250 crore as mentioned in their DRHP.
Why Invest In Pharmeasy Share
• The company has a first mover advantage in the industry due to which it has 
captured a wider market than any of it's peers. This first mover advantage has also 
helped pharmeasy to establish a strong brand name in the market.
• The revenue of the company has grown by a massive 220% in FY'21 over FY'20 
which was majorly due to a huge surge in the demand for pharmaceuticals and 
healthcare products as a result of rise in pandemic.
• The company has recently entered into the diagnostic test provision services 
segment, which has allowed it to tap a larger market due to increased awareness 
on self care and precaution as a result of the widespread pandemic in the country.
Pharmeasy Revenue Growth
• The company's revenue (pharmeasy Revenue Growth) has grown 
massively increasing from INR 737.4 Cr in FY'20 to INR 2360.6 Cr in FY'21. 
This increase is mainly attributable to the massive rise in demand for 
pharmaceuticals due to the spread the of Covid-19 pandemic across the 
country. 
THANKS FOR VISITING
PLANIFY
Visit for more Info
Pharmeasy Share Price